Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...

2025年，减肥药市场风头最劲的“黑马”之一，非临床阶段生物科技公司 Structure Therapeutics（GPCR）莫属。该生物科技股票的股价在去年12月因一款名为 aleniglipron ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Investing.com - Cantor Fitzgerald重申对 Structure Therapeutics (NASDAQ:GPCR) 的"增持"评级，目标价为101.00美元，相较于当前62.77美元的价格有显著上涨空间。这与分析师的普遍共识一致，整体评级为"强烈买入"，目标价区间在65美元至130美元之间。 该投资公司的决定是在其描述的"aleniglipron近期强劲的肥胖症数据 ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have ...